At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 236 enrolled
Drug / intervention
CD1579 2.5% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-blinded, Vehicle-controlled Parallel Group Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.
In Brief
A Phase 2 clinical trial evaluating CD1579 2.5%, CD1579 5%, and 1 other intervention for Acne Vulgaris. Completed, enrolled 236 participants across 6 sites.
Detailed Summary
This study is to assess the efficacy and safety of two concentrations of CD1579 (2.5% and 5%) versus vehicle in the treatment of acne vulgaris in the Japanese patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 2014
Enrollment StartMar 2014
Primary CompletionOct 2014
TodayJul 2026
First PostedFeb 27, 2014
Enrollment StartMar 1, 2014
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.3 years ago
Interventions
CD1579 2.5%drug
CD1579 5%drug
Vehicledrug